BriaCell Therapeutics Corp. (BCTX) EPS (Basic) (2021 - 2026)

BriaCell Therapeutics has reported EPS (Basic) for 6 years, with the latest figure at -$1.02 in Q2 2026.

• Quarterly EPS (Basic) rose 93.96% year-over-year to -$1.02 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$4.37 (up 94.66% YoY) and the FY2025 annual result came in at -$62.19, down 42.38% from the prior year.
• EPS (Basic) grew to -$1.02 in Q2 2026 per BCTX's latest filing, from -$2.65 in the prior quarter.
• Over five years, EPS (Basic) peaked at $56.33 in Q4 2023 and troughed at -$114.1 in Q3 2023.
• A 5-year average of -$32.98 and a median of -$29.53 in 2024 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2023 and 2025: EPS (Basic) surged 626.64% in 2023, then plunged 205.38% in 2025.
• Over 5 years, EPS (Basic) stood at -$10.7 in 2022, then soared by 626.64% to $56.33 in 2023, then slumped by 158.0% to -$32.67 in 2024, then soared by 86.48% to -$4.42 in 2025, then surged by 76.79% to -$1.02 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$1.02, -$2.65, and -$4.42 for Q2 2026, Q1 2026, and Q4 2025 respectively.